Large randomized trials (e.g., EMPOWER-4, DUPLEX-Combo) are required to define sequencing and synergy across cardiorenal endpoints
10.1042/BST20200270 Summary Keywords GLP-1, immunemetabolic signaling, metabolic disease, neuroendocrine peptides, orphan receptors, peptide therapeutics, polypharmacology Citation Niazi SK (2026) Beyond GLP-1: underexplored peptidereceptor systems as the next frontier in drug discovery
Forward-Looking Strategies: Ensuring Patient Safety and Informed Use As the legal proceedings unfold, it is imperative for all stakeholders, including pharmaceutical companies, healthcare providers, regulatory bodies, and patients, to collaborate in promoting the safe and informed use of semaglutide
Shima Hadidchi, MD , stands out as a trusted provider for Semaglutide GLP-1 weight loss treatment , offering personalized care tailored to each patients unique health goals